Skip To Main Content
Søren Hough on Muck Rack

Søren Hough

(He/Him)
London
As seen in: BioXconomy, RogerEbert.com, Mary Ann Liebert, Inc., Future Medicine, The Massachusetts Daily Collegian, BioProcess International Magazine, Science For The People Magazine
Covers:  Science, Politics, Ethics, History, Film, Television

Get in touch with Søren

Contact Søren, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Søren Hough’s Biography

Read Full Bio →

Chaz Ebert — writer, publisher, and wife of the late critic Roger Ebert — once called me "a hipster scientist and film critic."

I am a science writer and editor with a passion for positioning scientific research within its social context. I have led multiple teams of journalists at international publications toward creating premiere resources for accurate information on emerging technologies. I am comfortable writing for both general and expert audiences with a goal of making complex ideas unde…

Søren Hough’s Journalist Portfolio

See all →
Antibody-peptide fusions challenge ADCs for therapeutic throne

Antibody-peptide fusions challenge ADCs for therapeutic throne

ATB Therapeutics' fusions are tackling blood cancers, solid tumors, and autoimmune disorders.

View article →
Moving beyond conjugates with antibody-oligo carriers

Moving beyond conjugates with antibody-oligo carriers

Roche researchers push ASO masking to create more precise therapeutics for neurodegenerative disease.

View article →
Making the Medicine: Cheng Yi Chen on scaling drugs from lab to launch

Making the Medicine: Cheng Yi Chen on scaling drugs from lab to launch

Podcast discussion with Asymchem CTO Cheng Yi Chen where we discuss producing drugs at scale so that they can…

View article →
Eli Lilly’s Michael Kopach says retatrutide leads in obesity treatment and CMC innovation

Eli Lilly’s Michael Kopach says retatrutide leads in obesity treatment and CMC innovation

The pharma company’s latest peptide is so effective, it’s raising eyebrows among medical professionals.

View article →
Adaptable manufacturing platforms enable in vivo mRNA-LNP delivery, says Lonza

Adaptable manufacturing platforms enable in vivo mRNA-LNP delivery, says Lonza

Manufacturing expert Telmo Graça believes a more agile CMC process will reduce costs and bring drugs to marke…

View article →
Genetic mechanic: Stanley Crooke on oligos for nano-rare disease

Genetic mechanic: Stanley Crooke on oligos for nano-rare disease

How belief in antisense oligo technology helped an industry leader prove doubters wrong.

View article →

Articles

Breakthrough peptide repairs nerves after spinal cord injury in clinical trial

|
By Søren Hough
| BioXconomy
Spinal cord injuries have devastating consequences and impact more than 15 million people worldwide. Damage to spinal nerves can lead to pain, weakness, and even tetraplegia, where all four limbs are severely impaired. Part of the reason these injuries have no disease-modifying treatments is that nerves cannot be revived after they die – or at least, that’s what we thought. Now, novel therapeutic modalities like gene therapies and peptides could reverse at least some of the damage for patients.
Open in Who Shared Issue with article?

Antibody-peptide fusions challenge ADCs for therapeutic throne

|
By Millie Hoe, Søren Hough
| BioXconomy
Antibody-drug conjugates (ADCs) have seen successes and setbacks since they hit the clinic in the early 2000s. These drugs showed promise in directing cancer drugs toward specific tissues but have struggled with off-target toxicities and cytotoxic payloads – sometimes leading to issues with regulators. Biotechnology company ATB Therapeutics has now engineered what they call “atbodies” to help resolve these issues. Atbodies are antibodies fused to a peptide linker and enzymatic payload.
Open in Who Shared Issue with article?

Moving beyond conjugates with antibody-oligo carriers

|
By Søren Hough
| BioXconomy
Roche researchers push ASO masking to create more precise therapeutics for neurodegenerative disease. Oligos are sticky. They bind easily to proteins and other molecules, sometimes getting stuck on the cell surface and ablating their activity altogether. This is no less true for antibody-oligo conjugates (AOCs): complex molecules that combine the longevity of antibodies with genetic regulation by oligos.
Open in Who Shared Issue with article?
See all 87 articles

Awards

August Monthly Showcase Winner

2024 - Early Career Science Writer Network

I was selected by the Early Career Science Writer Network (affiliated with the Association of British Science Writers) as the winner of the August Monthly Showcase for my story on using brain parasites to deliver therapeutic proteins to patients: https://www.bioxconomy.com/modalities/harnessing-brain-parasites-for-protein-delivery

View Award